The Significance of BRAFV600E Mutation in Thyroid Cancer in Terms of Novel Targeted Therapies - Overview of Current Knowledge and Studies.
Klin Onkol
; 31(5): 339-344, 2018.
Article
en En
| MEDLINE
| ID: mdl-30541319
Palabras clave
or services used in the study. The Editorial Board declares that the manuscript met the ICMJE recommendation for biomedical papers. Submitted: 4. 6. 2018 Accepted: 1. 8. 2018; products; thyroid cancer - BRAF mutation - biological therapy - tyrosine kinase inhibitor - MEK inhibitor The authors declare they have no potential conflicts of interest concerning drugs
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Neoplasias de la Tiroides
/
Proteínas Proto-Oncogénicas B-raf
/
Inhibidores de Proteínas Quinasas
Tipo de estudio:
Guideline
/
Prognostic_studies
Límite:
Humans
Idioma:
En
Revista:
Klin Onkol
Asunto de la revista:
NEOPLASIAS
Año:
2018
Tipo del documento:
Article